Xeris Pharmaceuticals Inc (XERS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.04B
Last updated: Nov 17, 2026 at 11:06 AM ET
Xeris Pharmaceuticals Inc (XERS) P/E Ratio & Valuation Multiples
Xeris Pharmaceuticals (XERS) trades at 139.2x trailing earnings and 8.2x sales. Its P/S of 8.2x is above its 5-year median of 2.7x. Its forward P/E is 85.5x. The median P/E across 11 similar companies is 10.7x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 62.8% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 139.2x |
| Forward P/E | 85.5x |
| Price to sales | 8.2x |
| Price to book | 61.9x |
| EV/EBITDA | 48.8x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 100.0% above 4.1x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 8.2x | 2.7x | 4.1x |
Valuation History
Over the 8 year ends shown, its P/S ranged from 1.6x in 2022 to 68.1x in 2019.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $7.85 | 4.4x | 103.3x |
| 2024 | $3.39 | 2.5x | N/A |
| 2023 | $2.35 | 2.0x | N/A |
| 2022 | $1.33 | 1.6x | 4.0x |
| 2021 | $2.93 | 4.8x | 3.8x |
| 2020 | $4.92 | 11.0x | 7.8x |
| 2019 | $7.05 | 68.1x | 13.2x |
| 2018 | $17.00 | 44.6x | 4.7x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About XERS
What is XERS's forward P/E ratio?
Xeris Pharmaceuticals has a forward P/E ratio of 85.5x.
Is XERS stock overvalued?
GNG's valuation label for XERS is Overvalued. Its P/E of 139.2x compares with a median of 10.7x across 11 similar companies.
What is XERS's price to sales ratio?
Xeris Pharmaceuticals has a price to sales ratio of 8.2x.
XERS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors